Background

Tim Goodship was Professor of Renal Medicine and Honorary Consultant Nephrologist in the Newcastle upon Tyne Hospitals NHS Foundation Trust until his retirement in  2016. He is now the Associate Dean for Clinical Informatics in the Faculty of Medical Sciences.  He qualified at Guys Hospital having also undertaken an intercalated degree in Pharmacology. He trained in renal medicine in Newcastle and Boston.

Publications

• Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Journal of Immunology 2018, 200(7), 2464-2478.
• Goodship THJ, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJH, Alpers CE, Appel GB, Ardissino G, Ariceta G, Arici M, Bagga A, Bajema IM, Blasco M, Burke L, Cairns TD, Carratala M, D'Agati VD, Daha MR, De Vriese AS, Dragon-Durey M-A, Fogo AB, Galbusera M, Gale DP, Haller H, Johnson S, Jozsi M, Karpman D, Lanning L, Le Quintrec M, Licht C, Loirat C, Monfort F, Morgan BP, Noel L-H, O'Shaughnessy MM, Rabant M, Rondeau E, Ruggenenti P, Sheerin NS, Smith J, Spoleti F, Thurman JM, van de Kar NCAJ, Vivarelli M, Zipfel PF. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. In: Kidney International. 2017, Elsevier B.V.
• Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh P, Wong EKS, Booth C, Kerecuk L, Salama A, Almond M, Inward C, Goodship TH, Sheerin N, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney International 2017, 92(5), Pages 1261-1271.
• Darlow JM, Darlay R, Dobson MG, Stewart A, Charoen P, Southgate J, Baker SC, Xu Y, Hunziker M, Lambert HJ, Green AJ, Santibanez-Koref M, Sayer JA, Goodship THJ, Puri P, Woolf AS, Kenda RB, Barton DE, Cordell HJ. Genome-wide linkage and association study implicates the 10q26 region as a major genetic contributor to primary nonsyndromic vesicoureteric reflux. Scientific Reports 2017, 7, 14595.
• Challis RC, Ring T, Xu Y, Wong EKS, Flossmann O, Roberts ISD, Ahmed S, Wetherall M, Salkus G, Brocklebank B, Fester J, Strain L, Wilson V, Wood KM, Marchbank KJ, Santibanez-Koref M, Goodship THJ, Kavanagh D. Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease. Journal of the American Society of Nephrology 2017, 28(4), 1084-1091.
• Challis RC, Araujo GSR, Wong EKS, Anderson HE, Awan A, Dorman AM, Waldron M, Wilson V, Brocklebank V, Strain L, Morgan BP, Harris CL, Marchbank KJ, Goodship THJ, Kavanagh D. A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H–Related 3 Gene in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology 2016, 27(6), 1617-1624.
• Sheerin N, Kavanagh D, Goodship THG, Johnson S. A national specialised service in England for atypical haemolytic uraemic syndrome – the first year’s experience. QJM 2016, 109(1), 27-33.
• Taton O, Delhaye M, Stordeur P, Goodship T, Le Moine A, Massart A. An unusual case of haemolytic uraemic syndrome following endoscopic retrograde cholangiopancreatography rapidly improved with eculizumab. Acta Gastro-Enterologica Belgica 2016, 79(2), 257-261.
• Gleeson PJ, Wilson V, Cox TE, Sharma SD, Smith-Jackson K, Strain L, Lappin D, McHale T, Kavanagh D, Goodship THJ. Chromosomal rearrangement – a rare cause of complement factor I associated atypical haemolytic uraemic syndrome. Immunobiology 2016, 221(10), 1124-1130.
• Morton M, Chinnadurai R, Ahmed S, Sharma A, Dutt T, Bhutani S, Denley H, Augustine T, Goodship T, Sheerin N, Picton M. Management of Recurrent aHUS After Adult Kidney transplantation Despite Eculizumab Prophylaxis. In: 2016 American Transplant Congress. 2016, Boston, USA: Wiley-Blackwell Publishing, Inc.
• Riddell A, Goodship T, Bingham C. Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab. Clinical Nephrology 2016, 86(4), 200-202.
• Phillips EH, Westwood JP, Brocklebank V, Wong EKS, Tellez JO, Marchbank KJ, McGuckin S, Gale DP, Connolly J, Goodship THJ, Kavanagh D, Scully MA. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis 2016, 14(1), 175-185.
• Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship THJ, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJH. Atypical aHUS: State of the art. Molecular Immunology 2015, 67(1), 31-42.
• Watson R, Wearmouth E, McLoughlin A-C, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship THJ, Marchbank KJ. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology 2015, 63(2), 287-296.
• Cullinan N, Gorman KM, Riordan M, Waldron M, Goodship THJ, Awan A. Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome. Pediatrics 2015, 135(6), E1506-E1509.
• Wong EKS, Miller E, Brocklebank V, Bellamy C, Harris C, Neary J, Metcalfe W, Atkinson J, Goodship THJ, Kavanagh D, Richards A. Characterisation of a C3 Mutation with Increased Resistance to Complement Regulation in an Individual with Recurrent C3GN in a Renel Transplant. In: 52nd Congress of the ERA-EDTA. 2015, London, UK: Oxford University Press.
• Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen D, Delmas Y, Douglas K, Furman R, Gaber O, Goodship T, Herthelius M, Hourmant M, Legendre C, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International 2015, 87, 1061-1073.
• Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJH, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 2015, 125(15), 2359-2369.
• Vivante A, Kleppa MJ, Schulz J, Kohl S, Sharma A, Chen J, Shril S, Hwang DY, Weiss AC, Kaminski MM, Shukrun R, Kemper MJ, Lehnhardt A, Beetz R, Sanna-Cherchi S, Verbitsky M, Gharavi AG, Stuart HM, Feather SA, Goodship JA, Goodship THJ, Woolf AS, Westra SJ, Doody DP, Bauer SB, Lee RS, Adam RM, Lu W, Reutter HM, Kehinde EO, Mancini EJ, Lifton RP, Tasic V, Lienkamp SS, Juppner H, Kispert A, Hildebrandt F. Mutations in TBX18 Cause Dominant Urinary Tract Malformations via Transcriptional Dysregulation of Ureter Development. American Journal of Human Genetics 2015, 97(2), 291-301.
• Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2015.
• Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship THJ, Kavanagh D, Unsal A. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: A case report. Journal of Medical Case Reports 2015, 9, 92.
• Wong EKS, Marchbank K, Pappworth I, Walters R, Lomax-Browne H, Harris C, Morgan P, Pickering M, Goodship THJ, Malcomson R, Cook T, Johnson S, MPGN C3G Rare Dis Grp. The national study of membranoproliferative glomerulonephrtis and C3 glomerulopathy - characterisation of the paediatric cohort. In: 52nd ERA-EDTA Congress. 2015, London, UK: Oxford University Press.
• Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Cordoba SR, Noris M, Pickering M, Smith R. The role of complement in C3 glomerulopathy. Molecular Immunology 2015, 67(1), 21-30.
• Iqbal Z, Wood K, Carter V, Goodship TH, Brown AL, Sheerin NS. Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: a case report demonstrating successful treatment with Eculizumab. Transplantation Proceedings 2015, 47(7), 2258–2261.
• Stuart HM, Roberts NA, Hilton EN, McKenzie EA, Daly SB, Hadfield KD, Rahal JS, Gardiner NJ, Tanley SW, Lewis MA, Sites E, Angle B, Alves C, Lourenco T, Rodrigues M, Calado A, Amado M, Guerreiro N, Serras I, Beetz C, Varga RE, Silay MS, Darlow JM, Dobson MG, Barton DE, Hunziker M, Puri P, Feather SA, Goodship JA, Goodship THJ, Lambert HJ, Cordell HJ, Saggar A, Kinali M, Lorenz C, Moeller K, Schaefer F, Bayazit AK, Weber S, Newman WG, Woolf AS, UK VUR Study Grp, 4C Study Grp. Urinary Tract Effects of HPSE2 Mutations. Journal of the American Society of Nephrology 2015, 26(4), 797-804.
• Ring T, Pedersen BB, Salkus G, Goodship THJ. Use of eculizumab in crescentic IgA nephropathy: Proof of principle and conundrum?. Clinical Kidney Journal 2015, 8(5), 489-491.
• Blom AM, Volokhina EB, Fransson V, Stromberg P, Berghard L, Viktorelius M, Mollnes TE, Lopez-Trascasa M, van den Heuvel LP, Goodship TH, Marchbank KJ, Okroj M. A novel method for direct measurement of complement convertases activity in human serum. Clinical & Experimental Immunology 2014, 178(1), 142-153.
• Brocklebank V, Wong EKS, Fielding R, Goodship THJ, Kavanagh D. Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri. Clinical Kidney Journal 2014, 7(3), 286-288.
• Wong EKS, Anderson HE, Herbert AP, Challis RC, Brown P, Reis GS, Tellez JO, Strain L, Fluck N, Humphrey A, Macleod A, Richards A, Ahlert D, Santibanez-Koref M, Barlow PN, Marchbank KJ, Harris CL, Goodship THJ, Kavanagh D. Characterization of a Factor H Mutation That Perturbs the Alternative Pathway of Complement in a Family with Membranoproliferative GN. Journal of American Society of Nephrology 2014, 25(11), 2425-2433.
• Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. Journal of Clinical Investigation 2014, 124(1), 145-155.
• Sansbury FH, Cordell HJ, Bingham C, Bromilow G, Nicholls A, Powell R, Shields B, Smyth L, Warwicker P, Strain L, Wilson V, Goodship JA, Goodship THJ, Turnpenny PD. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. Journal of Medical Genetics 2014, 51(11), 756-764.
• Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. British Journal of Haematology 2014, 164(6), 759-766.
• Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Seminars in Nephrology 2013, 33(6), 508-530.
• Forbes TA, Bradbury MG, Goodship THJ, McKiernan PJ, Milford DV. Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: A tertiary case series. Pediatric Transplantation 2013, 17(3), E93-E99.
• Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, de Cordoba SR, Pinto S, Goodship THJ, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party Complement. Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. Journal of the American Society of Nephrology 2013, 24(3), 475-486.
• Wong EKS, Goodship THJ, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology 2013, 56(3), 199-212.
• Holmes LV, Strain L, Staniforth SJ, Moore I, Marchbank K, Kavanagh D, Goodship JA, Cordell HJ, Goodship THJ. Determining the Population Frequency of the CFHR3/CFHR1 Deletion at 1q32. PLoS ONE 2013, 8(4), e60352.
• Sofat R, Mangione PP, Gallimore JR, Hakobyan S, Hughes TR, Shah T, Goodship T, D'Aiuto F, Langenberg C, Wahreham N, Morgan BP, Pepys MB, Hingorani AD. Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. Journal of Immunological Methods 2013, 390(1-2), 63-73.
• Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatric Nephrology 2013, 28(8), 1315-1318.
• Wilson V, Darlay R, Wong W, Wood KM, McFarlane J, Schejbel L, Schmidt IM, Harris CL, Tellez J, Hunze EM, Marchbank K, Goodship JA, Goodship THJ. Genotype/Phenotype Correlations in Complement Factor H Deficiency Arising From Uniparental Isodisomy. American Journal of Kidney Diseases 2013, 62(5), 978-983.
• Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine 2013, 368(23), 2169-2181.
• Teoh CW, Bates M, Walsh B, Lynch B, Menavari A, Goodship T, Dolan NM, Riordan M, Waldron M, Awan A. Use of Eculizumab in atypical haemolyticuraemic syndrome associated with complement factor B variant. In: IPNA Congress 2013. 2013, Shanghai, China: Springer.
• Francis NJ, McNicholas B, Awan A, Waldron M, Reddan D, Sadlier D, Kavanagh D, Strain L, Marchbank KJ, Harris CL, Goodship THJ. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 2012, 119(2), 591-601.
• Ermini L, Goodship THJ, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Molecular Immunology 2012, 49(4), 640-648.
• Ermini L, Wilson IJ, Goodship THJ, Sheerin NS. Complement polymorphisms: Geographical distribution and relevance to disease. Immunobiology 2012, 217(2), 265-271.
• Goodship THJ, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ. Factor H autoantibodies in membranoproliferative glomerulonephritis. Molecular Immunology 2012, 52(3-4), 200-206.
• Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L, Ward R, Plant N, Nailescu C, Goodship TH, Marchbank KJ. Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?. Clinical Journal of the American Society of Nephrology 2012, 7(3), 417-426.
• Brown JH, Tellez J, Wilson V, Mackie IJ, Scully M, Tredger MM, Moore I, McDougall NI, Strain L, Marchbank KJ, Sheerin NS, O'Grady J, Harris CL, Goodship THJ. Postpartum aHUS Secondary to a Genetic Abnormality in Factor H Acquired Through Liver Transplantation. American Journal of Transplantation 2012, 12(6), 1632-1636.
• Paixão-Cavalcante D, López-Trascasa M, Skattum L, Giclas PC, Goodship TH, Rodríguez de Córdoba S, Truedsson L, Morgan BP, Harris CL. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney International 2012, 82(10), 1084-1092.
• Zhao J, Wu H, Khosravi M, Cui HJ, Qian XX, Kelly JA, Kaufman KM, Langefeld CD, Williams AH, Comeau ME, Ziegler JT, Marion MC, Adler A, Glenn SB, Alarcon-Riquelme ME, Pons-Estel BA, Harley JB, Bae SC, Bang SY, Cho SK, Jacob CO, Vyse TJ, Niewold TB, Gaffney PM, Moser KL, Kimberly RP, Edberg JC, Brown EE, Alarcon GS, Petri MA, Ramsey-Goldman R, Vila LM, Reveille JD, James JA, Gilkeson GS, Kamen DL, Freedman BI, Anaya JM, Merrill JT, Criswell LA, Scofield RH, Stevens AM, Guthridge JM, Chang DM, Song YW, Park JA, Lee EY, Boackle SA, Grossman JM, Hahn BH, Goodship THJ, Cantor RM, Yu CY, Shen N, Tsao BP, BIOLUPUS Network, GENLES Network. Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility. PLoS Genetics 2011, 7(5), e1002079.
• Kavanagh D, Goodship THJ. Atypical Hemolytic Uremic Syndrome, Genetic Basis, and Clinical Manifestations. HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM 2011, 15-20.
• Kavanagh D, Goodship T. Haemolytic Uraemic Syndrome. Nephron Clinical Practice 2011, 118(1), C37-C42.
• Simms RJ, Sayer JA, Quinton R, Walker M, Ellard S, Goodship THJ. Monogenic diabetes, renal dysplasia and hypopituitarism: a patient with a HNF1A mutation. QJM 2011, 104(10), 881-883.
• Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP. Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Medicine 2011, 8(3), e1001013.
• Kim JJ, Goodship THJ, Tizard J, Inward C. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatric Nephrology 2011, 26(11), 2073-2076.
• Lambert HJ, Stewart A, Gullett AM, Cordell HJ, Malcolm S, Feather SA, Goodship JA, Goodship THJ, Woolf AS, UK VUR Study Grp. Primary, Nonsyndromic Vesicoureteric Reflux and Nephropathy in Sibling Pairs: A United Kingdom Cohort for a DNA Bank. Clinical Journal of the American Society of Nephrology 2011, 6(4), 760-766.
• Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T. Successful Simultaneous Liver-Kidney Transplant in an Adult With Atypical Hemolytic Uremic Syndrome Associated With a Mutation in Complement Factor H. American Journal of Kidney Diseases 2011, 58(1), 109-112.
• Wilson CH, Brown AL, White SA, Goodship THJ, Sheerin NS, Manas DM. Successful Treatment of De Novo Posttransplant Thrombotic Microangiopathy With Eculizumab. Transplantation 2011, 92(8), E42-E43.
• Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship THJ, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115(2), 379-387.
• Hughes AE, Orr N, Cordell HJ, Goodship T. Associations of CFHR1-CFHR3 deletion and a CFH snp to age-related macular degeneration are not independent reply. Nature Genetics 2010, 42(7), 555-556.
• Kavanagh D, Goodship THJ. Atypical hemolytic uremic syndrome. Current Opinion in Hematology 2010, 17(5), 432-438.
• Taylor CM, Machin S, Wigmore SJ, Goodship THJ, Renal Association, British Committee for Standards in Haematology, British Transplantation Society. Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom. British Journal of Haematology 2010, 148(1), 37-47.
• Dhillon B, Wright AF, Tufail A, Pappworth I, Hayward C, Moore I, Strain L, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Armbrecht AM, Laude A, Deary IJ, Staniforth SJ, Holmes LV, Goodship THJ, Marchbank KJ. Complement Factor H Autoantibodies and Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science 2010, 51(11), 5858-5863.
• Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatric Nephrology 2010, 25(12), 2431-2442.
• Johnson SA, Williams JM, Hakobyan S, Richards A, Perkins SJ, Marchbank KJ, Goodship THJ, Morgan BP, Taylor CM, Savage COS. Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome-A pedigree revisited. Molecular Immunology 2010, 47(7-8), 1585-1591.
• Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation. American Journal of Kidney Diseases 2010, 55(4), 708-711.
• Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschenes G, Goodship THJ, Majoie C, Davin JC, Blanc R, Savatovsky J, Moret J, Fremeaux-Bacchi V. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrology, Dialysis, Transplantation 2010, 25(10), 3421-3425.
• Goodship THJ, Kavanagh D. Pulling the Trigger in Atypical Hemolytic Uremic Syndrome: The Role of Pregnancy. Journal of the American Society of Nephrology 2010, 21(5), 731-732.
• Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. Clinical Journal of the American Society of Nephrology 2010, 5(10), 1844-1859.
• Hughes A, Orr N, Cordell H, Goodship T. Reply to “Associations of CFHR1–CFHR3 deletion and a CFH SNP to age-related macular degeneration are not independent”. Nature Genetics 2010, 42(7), 555-556.
• Haller W, Milford DV, Goodship THJ, Sharif K, Mirza DF, McKiernan PJ. Successful Isolated Liver Transplantation in a Child with Atypical Hemolytic Uremic Syndrome and a Mutation in Complement Factor H. American Journal of Transplantation 2010, 10(9), 2142-2147.
• Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, Strain L, Sebire N, Shroff R, Marks SD, Goodship THJ, Rees L. Successful Renal Transplantation in Factor H Autoantibody Associated HUS with CFHR1 and 3 Deficiency and CFH Variant G2850T. American Journal of Transplantation 2010, 10(1), 168-172.
• Kavanagh D, Richards A, Goodship T, Jalanko H. Transplantation in Atypical Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis 2010, 36(6), 653-659.
• Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, Strain L, Goodship THJ, Meneses-Oliveira C. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Renal Failure 2010, 32(6), 753-756.
• Cordell HJ, Darlay R, Charoen P, Stewart A, Gullett AM, Lambert HJ, Malcolm S, Feather SA, Goodship THJ, Woolf AS, Kenda RB, Goodship JA, UK VUR Study Grp. Whole-Genome Linkage and Association Scan in Primary, Nonsyndromic Vesicoureteric Reflux. Journal of the American Society of Nephrology 2010, 21(1), 113-123.
• Davin JC, Knobbe I, Bouts AH, Groothoff JW, Strain L, Goodship THJ. In atypical HUS (aHUS), the EKZ-AMC protocol of plasma therapy (PT) prevents a chronic renal failure, allows successful kidney transplantation and avoid cerebral arteries stenosis. Pediatric Nephrology 2009, 24(4), 907-907.
• Edey M, Strain L, Ward R, Ahmed S, Thomas T, Goodship TH. Is complement factor H a susceptibility factor for IgA nephropathy?. Molecular Immunology 2009, 46(7), 1405-1408.
• Saland J, Ruggenenti P, Remuzzi G, Bekassy Z, Bensman A, Bresin E, Colledan M, Camilla R, Coppo R, Cruzado-Garrit J, Daina E, Fremeaux-Bacchi V, Goodship T, Gridelli B, Hugo C, Karpman D, Jalanko H, Loirat C, Hijosa M, McKiernan P, Noris M, De Cordoba S, Rota G, Sanchez-Corral P, Skerka C, Tartufari A, Zipfel P. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 2009, 20(5), 940-949.
• Davin JC, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, Goodship T. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatric Nephrology 2009, 24(9), 1757-1760.
• Williams SE, Reed AA, Galvanovskis J, Antignac C, Goodship T, Karet FE, Kotanko P, Lhotta K, Moriniere V, Williams P, Wong W, Rorsman P, Thakker RV. Uromodulin mutations causing familial juvenile hyperuricaemic nephropathy lead to protein maturation defects and retention in the endoplasmic reticulum. Human Molecular Genetics 2009, 18, 2963-74.
• Blom AM, Bergström F, Edey MMJ, Diaz-Torres M, Kavanagh DG, Lampe AK, Goodship JA, Strain L, Moghal N, McHugh M, Inward C, Tomson C, Frémeaux-Bacchi V, Villoutreix BO, Goodship THJ. A Novel Non-Synonymous Polymorphism (p.Arg240His) in C4b-Binding Protein Is Associated with Atypical Hemolytic Uremic Syndrome and Leads to Impaired Alternative Pathway Cofactor Activity. Journal of Immunology 2008, 180(9), 6385-6391.
• Edey MM, Mead PA, Saunders RE, Strain L, Perkins SJ, Goodship THJ, Kanagasundaram NS. Association of a Factor H Mutation With Hemolytic Uremic Syndrome Following a Diarrheal Illness. American Journal of Kidney Diseases 2008, 51(3), 487-490.
• Noris M, Remuzzi G, Goodship T. Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Handbook of Systemic Autoimmune Diseases 2008, 7, 257-282.
• Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, Goodship JA, Fremeaux-Bacchi V, Remuzzi G, Goodship THJ, Atkinson JP. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology 2008, 45(1), 95-105.
• Lapeyraque A-L, Wagner E, Phan V, Clermont M-J, Merouani A, Fremeaux-Bacchi V, Goodship THJ, Robitaille P. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatric Nephrology 2008, 23(8), 1363-1366.
• Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship THJ, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008, 111(2), 624-632.
• Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, de Ligny BH, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJC, Goodship THJ, Atkinson JP. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112(13), 4948-4952.
• Davin JC, Strain L, Goodship THJ. Plasma therapy in atypical haemolytic uremic syndrome: Lessons from a family with a factor H mutation. Pediatric Nephrology 2008, 23(9), 1517-1521.
• Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Frémeaux-Bacchi V, Skerka C, Zipfel PF, Goodship THJ, Noris M, Remuzzi G, De Cordoba SR. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 2008, 19(3), 639-646.
• Uzonyi B, Richter H, Strobel S, Jozsi M, Skerka C, Licht C, Hoppe B, Kirschfink M, Hugo C, Wolf G, Strain L, Goodship THJ, Zipfel PF. The European MPGN registry. In: XXII International Complement Workshop. 2008, Basel, Switzerland: Molecular Immunology: Pergamon.
• Karpman D, Blom A, Goodship T, Sullivan KE. Anguish over angiopathy: Hemolytic uremic syndrome. Clinical Immunology 2007, 122(2), 135-138.
• Atkinson JP, Goodship THJ. Complement factor H and the hemolytic uremic syndrome. Journal of Experimental Medicine 2007, 204(6), 1245-1248.
• Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship THJ, Skerka C. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genetics 2007, 3(3), 0387-0392.
• Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship THJ, Atkinson JP. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Molecular Immunology 2007, 44(1-3), 111-122.
• Goodship T. Microangiopathies. Medicine 2007, 35(9), 510-511.
• Liszewski MK, Leung MK, Schraml B, Goodship THJ, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Molecular Immunology 2007, 44(7), 1570-1579.
• Gurreebun F, Hartley GH, Brown AL, Ward MC, Goodship THJ. Nutritional Screening in Patients on Hemodialysis: Is Subjective Global Assessment an Appropriate Tool?. Journal of Renal Nutrition 2007, 17(2), 114-117.
• Kavanagh D, Richards A, Fremeaux-Bacchi V, Noris M, Goodship T, Remuzzi G, Atkinson JP. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clinical Journal of the American Society of Nephrology 2007, 2(3), 591-596.
• Kavanagh D, Burgess R, Spitzer D, Richards A, Diaz-Torres ML, Goodship JA, Hourcade DE, Atkinson JP, Goodship THJ. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation. Molecular Immunology 2007, 44(12), 3162-3167.
• Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea De Jorge E, Goodship THJ, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodriguez De Cordoba S, Sanchez-Corral P, Skerka C, Zipfel PF, Perkins SJ. The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: Update and integration of membrane cofactor protein and factor I mutations with structural models. Human Mutation 2007, 28(3), 222-234.
• Kavanagh D, Goodship TH. Update on evaluating complement in hemolytic uremic syndrome. Current Opinion in Nephrology and Hypertension 2007, 16(6), 565-571.
• Jokiranta TS, Zipfel PF, Fremeaux-Bacchi V, Taylor CM, Goodship TJH, Noris M. Where next with atypical hemolytic uremic syndrome?. Molecular Immunology 2007, 44(16), 3889-3900.
• Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nature Genetics 2006, 38(10), 1173-1177.
• Saunders RE, Goodship THJ, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: Insights into the structural consequences of disease-associated mutations. Human Mutation 2006, 27(1), 21-30.
• Kavanagh D, Goodship THJ, Richards A. Atypical haemolytic uraemic syndrome. British Medical Bulletin 2006, 77-78(1), 5-22.
• Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship THJ. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Medicine 2006, 3(10), e431 (1957-1967).
• Goodship THJ. Atypical HUS and complement dysregulation. Journal of the American Society of Nephrology 2006, 17(7), 1775-1776.
• Davin JC, Olie KH, Verlaak R, Horuz F, Florquin S, Weening JJ, Groothoff JW, Strain L, Goodship THJ. Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: Concordant presentation, discordant response to treatment. American Journal of Kidney Diseases 2006, 47(2), e27-e30.
• Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ, Skerka C, Jokiranta TS, Meyers K, Wagner E, Robitaille P, Esparza-Gordillo J, Rodriguez de Cordoba S, Zipfel PF, Goodship THJ. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Human Mutation 2006, 27(3), 292-293.
• Kavanagh D, Kemp EJ, Richards A, Burgess RM, Mayland E, Goodship JA, Goodship THJ. Does complement factor B have a role in the pathogenesis of atypical HUS?. Molecular Immunology 2006, 43(7), 856-859.
• Goodship THJ. Factor H genotype-phenotype correlations: Lessons from aHUS, MPGN II, and AMD. Kidney International 2006, 70(1), 12-13.
• Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship THJ. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. American Journal of Transplantation 2006, 6(8), 1948-1952.
• Kavanagh D, Goodship THJ. Membrane cofactor protein and factor I: Mutations and transplantation. Seminars in Thrombosis and Hemostasis 2006, 32(2), 155-159.
• Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship THJ, Remuzzi G, Int Registry Recurrent Familial. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance-of genetic background. Clinical Journal of the American Society of Nephrology 2006, 1(1), 88-99.
• Boxall MC, Goodship THJ, Brown AL, Ward MC, Von Zglinicki T. Telomere shortening and haemodialysis. Blood Purification 2006, 24(2), 185-189.
• Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship THJ. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 2005, 16(7), 2150-2155.
• Olie KH, Goodship THJ, Verlaak R, Florquin S, Groothoff JW, Strain L, Weening JJ, Davin JC. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: Successful treatment with intensive plasma exchanges and ganciclovir. American Journal of Kidney Diseases 2005, 45(1), E12-E15.
• Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey M-A, Strain L, Loirat C, Deng H-W, Goodship THJ. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: Evidence from two independent cohorts. Journal of Medical Genetics 2005, 42(11), 852-856.
• Kemp EJ, Strain L, Diaz-Torres ML, Goodship JA, Goodship THJ. The development of atypical hemolytic uremic syndrome is not influenced by thrombophilia susceptibility factors [15]. Journal of Thrombosis and Haemostasis 2005, 3(9), 2128-2130.
• Olie KH, Florquin S, Groothoff JW, Verlaak R, Strain L, Goodship THJ, Weening JJ, Davin J-C. Atypical relapse of hemolytic uremic syndrome after transplantation. Pediatric Nephrology 2004, 19(10), 1173-1176.
• Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH. Challenges in the management if infantile factor H associated hemolytic uremic syndrome. Pediatric Nephrology 2004, 19(8), 908-911.
• Pirson Y, Lefebvrek C, Lambert C, Warwicker P, Goodship THJ. Familial hemolytic uremic syndrome: a privileged observation. Bulletin et Memoires de le Academie Royale de Medecine de Belgique 2004, 159(2), 191-194.
• Goodship THJ. Inherited dysregulation of the complement system. Bulletin et Memoires de le Academie Royale de Medecine de Belgique 2004, 159(2), 195-198.
• Jiang SS, Gitlin J, Deng FM, Liang FX, Lee A, Atala A, Bauer SB, Ehrlich GD, Feather SA, Goldberg JD, Goodship JA, Goodship THJ, Hermanns M, Hu FZ, Jones KE, Malcolm S, Mendelsohn C, Preston RA, Retik AB, Schneck FX, Wright V, Ye XY, Woolf AS, Wu XR, Ostrer H, Shapiro E, Yu J, Sun TT. Lack of major involvement of human uroplakin genes in vesicoureteral reflux: Implications for disease heterogeneity. Kidney International 2004, 66(1), 10-19.
• Liszewski MK, Schraml B, Leung M, Caudy AA, Kemp EJ, Goodship THJ, Atkinson JP. Modeling how deficiency of membrane cofactor protein (MCP; CD46) predisposes to atypical hemolytic uremic syndrome. In: Molecular Immunology: 20th International Complement Workshop. 2004, Honolulu, Hawaii, USA: Pergamon.
• Goodship THJ, Liszewski MK, Kemp EJ, Richards A, Atkinson JP. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends in Molecular Medicine 2004, 10(5), 226-231.
• Sayer JA, Carr G, Pearce SHS, Goodship THJ, Simmons NL. Disordered calcium crystal handling in antisense CLC-5-treated collecting duct cells. Biochemical and Biophysical Research Communications 2003, 300(2), 305-310.
• Roberts, R.G., Redfern, C.P.F., Goodship, T.H.J. Effect of insulin upon protein degradation in cultured human myocytes. European Journal of Clinical Investigation 2003, 33(10), 861-867.
• Richards A, Kemp EJ, Liszewski MK, Goodship JA, Wen LS, Atkinson JP, Goodship THJ. Familial haemolytic uraemic syndrome and mutations in membrane cofactor protein (MCP; CD46) of the complement system. In: Molecular Immunology: 9th European Meeting on Complement in Human Disease. 2003, Trieste, Italy: Pergamon.
• Richards A, Kemp EJ, Liszewski K, Goodship JA, Lampe AK, Decorte R, Muslumanoglu H, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship THJ. Familial hemolytic uremic syndrome and mutations in membrane cofactor protein (MCP; CD46) of the complement system. In: Journal of the American Society of Nephrology: 36th Annual Meeting of the American Society of Nephrology. 2003, San Diego, California, USA: American Society of Nephrology.
• Goodship THJ. Fibrinogen in hemodialysis: The worst of both worlds?. Kidney International 2003, 63(1), 379-380.
• Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship THJ. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(22), 12966-12971.
• Boxall MC, Keys B, von Zglinicki TW, Goodship THJ. Peripheral blood mononuclear cell telomere length is unaltered in hemodialysis despite increased oxidative stress. In: Journal of the American Society of Nephrology: 36th Annual Meeting of the American Society of Nephrology. 2003, San Diego, California, USA: American Society of Nephrology.
• Hampton P, Graham KA, Millar M, McCluskey S, Goodship THJ. Anodipsia nervosa a variant of anorexia in patients with end-stage renal disease. Nephrology, Dialysis, Transplantation 2002, 17(5), 942-943.
• Sayer JA, Carr G, Simmons NL, Goodship THJ. Antisense CLC-5 disrupts acidic endosomes and endocytosis in murine collecting duct cells. Journal of the American Society of Nephrology 2002, 13(supplement), 306A.
• Louden JD, Bartlett K, Reaich D, Edson R, Alexander C, Goodship THJ. Effects of feeding on albumin synthesis in hypoalbuminemic hemodialysis patients. Kidney International 2002, 62(1), 266-271.
• Hartley GH, Goodship THJ, Hoenich NA, Hawkins T, Fawcett PRW, McHugh MI, Tapson JS. Is decreased treatment time in hemodialysis patients harmful if solute clearance is maintained?. International Journal of Artificial Organs 2002, 25(9), 844-851.
• Perkins SJ, Goodship THJ. Molecular modelling of the C-terminal domains of factor H of human complement: A correlation between haemolytic uraemic syndrome and a predicted heparin binding site. Journal of Molecular Biology 2002, 316(2), 217-224.
• Donne RL, Abbs I, Barany P, Elinder CG, Little M, Conlon P, Goodship THJ. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. American Journal of Kidney Diseases 2002, 40(6), E22.
• Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., Gibson, G.J., Goodship, T.H.J. Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clinical Science 2002, 102(3), 353-361.
• Roberts, R.G., Redfern, C.P.F., Graham, K.A., Bartlett, K., Wilkinson, R., Goodship, T.H.J. Sodium bicarbonate treatment and ubiquitin gene expression in acidotic human subjects with chronic renal failure. European Journal of Clinical Investigation 2002, 32(7), 488-492.
• Bingham C, Ellard S, Cole TRP, Jones KE, Allen LIS, Goodship JA, Goodship THJ, Bakalinova-Pugh D, Russell GI, Woolf AS, Nicholls AJ, Hattersley AT. Solitary functioning kidney and diverse genital tract malformations associated with hepatocyte nuclear factor-1 beta mutations. Kidney International 2002, 61(4), 1243-1251.
• Perkins SJ, Gilbert HE, Aslam M, Hannan J, Holers VM, Goodship THJ. Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. In: Biochemical Society Transactions: Meeting on High-Throughput Screening - The Way Ahead. 2002, Bedford, UK: Portland Press Ltd.
• Richards A, Goodship JA, Goodship THJ. The genetics and pathogenesis of haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Current Opinion in Nephrology & Hypertension 2002, 11(4), 431-435.
• Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship THJ. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. American Journal of Human Genetics 2001, 68(2), 485-490.
• Ludecke HJ, Schaper J, Meinecke P, Momeni P, Gross S, von Holtum D, Hirche H, Abramowicz MJ, Albrecht B, Apacik C, Christen HJ, Claussen U, Devriendt K, Fastnacht E, Forderer A, Friedrich U, Goodship THJ, Greiwe M, Hamm H, Hennekam RCM, Hinkel GK, Hoeltzenbein M, Kayserili H, Majewski F, Mathieu M, McLeod R, Midro AT, Moog U, Nagai T, Niikawa N, Orstavik KH, Plochl E, Seitz C, Schmidtke J, Tranebjaerg L, Tsukahara M, Wittwer B, Zabel B, Gillessen-Kaesbach G, Horsthemke B. Genotypic and phenotypic spectrum in tricho-rhino-phalangeal syndrome types I and III. American Journal of Human Genetics 2001, 68(1), 81-91.
• Jagoe RT, Goodship THJ, Gibson GJ. Nutritional status of patients undergoing lung cancer operations. Annals of Thoracic Surgery 2001, 71(3), 929-935.
• Jagoe RT, Goodship THJ, Gibson GJ. The influence of nutritional status on complications after operations for lung cancer. Annals of Thoracic Surgery 2001, 71(3), 936-943.
• Sayer JA, Stewart GS, Boese SH, Gray MA, Pearce SHS, Goodship THJ, Simmons NL. The voltage-dependent of Cl- channel ClC-5 and plasma membrane Cl- conductances of mouse renal collecting duct cells (mIMCD-3). Journal of Physiology 2001, 536(3), 769-783.
• Louden JD, Roberts RG, Goodship THJ. Acid-Base in Renal Failure: What have isotope studies in humans told us about the nutritional effects of acidosis in dialysis?. Seminars in Dialysis 2000, 13(4), 247-251.
• Roberts RG, Louden JD, Goodship THJ. An assessment of the methods available to determine nutritional equilibrium in patients with chronic renal failure. Nephrology Dialysis Transplantation 2000, 15(12), 1906-1908.
• Buddles MRH, Donne RL, Richards A, Goodship J, Goodship THJ. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. American Journal of Human Genetics 2000, 66(5), 1721-1722.
• Goodship JA, Buddles MRH, Richards A, Donne RL, Warwicker P, Goodship THJ. Factor H mutation in familiar and sporadic hemolytic uremic syndrome. In: AMERICAN JOURNAL OF HUMAN GENETICS. 2000.
• Goodship THJ, Stoddart JT, Martinek V, Geetha D, Brown AL, Ward MK, Kerr DNS, Owen JP, Wilkinson R. Long-term follow-up of patients presenting to adult nephrologists with chronic pyelonephritis and 'normal' renal function. QJM - Monthly Journal of the Association of Physicians 2000, 93(12), 799-803.
• Feather SA, Malcolm S, Woolf AS, Wright V, Blaydon D, Reid CJD, Flinter FA, Proesmans W, Devriendt K, Carter J, Warwicker P, Goodship THJ, Goodship JA. Primary, nonsyndromic vesicoureteric reflux and its nephropathy is genetically heterogeneous, with a locus on chromosome 1. American Journal of Human Genetics 2000, 66(4), 1420-1425.
• Malcolm S, Feather S, Woolf AS, Wright V, Blaydon D, Reid CJD, Flinter FA, Proesmans W, Devriendt K, Warwicker P, Goodship TH, Goodship JA. A major locus for vesicoureteric reflux and its nephropathy. In: American Journal of Human Genetics. 1999, Cell Press.
• Louden JD, Roberts RR, Goodship THJ. Acidosis and nutrition. In: Symposium on Renal Bone Disease. 1999, Manchester, England: Wiley-Blackwell Publishing, Inc.
• Hartley GH, Goodship THJ, Hawkins T, Fawcett PRW, Tapson JS. Adequacy of haemodialysis - the long and the short of it. In: The Renal Association Meeting. 1999, London, England: Nature Publishing Group.
• Warwicker P, Neild G, Goodship THJ. Angiotensin converting enzyme inhibitors (ACE-I) and bilateral nephrectomy in the treatment of hypertension in non-diarrhoeal haemolytic uraemic syndrome (d-HUS) - a retrospective study. In: The Renal Association Meeting. 1999, Bristol, England: Nature Publishing Group.
• Hoenich NA, Pearce C, Goodship THJ, Ward MK. Audit of hospital haemodialysis delivery. In: The Renal Association Meeting. 1999, Bristol, England: Nature Publishing Group.
• Goodship THJ, Owen JP, Stoddart JT, Martinek V, Geetha D, Ward MK, Wilkinson R. Chronic pyelonephritis. A re-evaluation of prognostic factors for the development of renal impairment. In: The Renal Association Meeting. 1999, London, England: Nature Publishing Group.
• Jones CH, Goodship THJ, Bartlett K, Newstead CG. Does clenbuterol affect whole body protein turnover in adults with end-stage renal failure managed by CAPD?. In: The Renal Association Meeting. 1999, London, England: Nature Publishing Group.
• Warwicker P, Donne RL, Goodship JA, Goodship THJ, Howie AJ, Kumararatne DS, Thompson RA, Taylor CM. Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrology Dialysis Transplantation 1999, 14(5), 1229-1233.
• Hartley GH, Goodship THJ, Hoenich NA, Tapson JS. The control of acidosis - short vs. long haemodialysis. In: The Renal Association Meeting. 1999, Bristol, England: Nature Publishing Group.
• Warwicker P, Goodship JA, Goodship THJ. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine 1999, 340(17), 1368-1369.
• Follows,G.A., Mathew,J., Lucas,S., Black,M.J.M., Goodship,T.H.J. Cutaneous botryomycosis in a patient with lupus nephritis. Nephrology Dialysis Transplantation 1998, 13, 3200-3201.
• Graham,K.A., Goodship,T.H.J. Does metabolic acidosis have clinically important consequences in dialysis patients?. Seminars in Dialysis 1998, 11, 14-15.
• Warwicker,P., Goodship,T.H.J., Donne,R.L., Pirson,Y., Nicholls, A., Ward,R.M., Turnpenny, P., Goodship,J.A. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney International 1998, 53, 836-844.
• Goodship,T.H.J. What is the relationship between metabolic acidosis and nutritional status in dialysis patients?. American Journal of Kidney Diseases 1998, 31, 884-886.
• P. Warwicker,T.H.J. Goodship,S. Pedler,M.K. Ward. Acute renal failure with hypocomplementaemic microangiopathy secondary to presumed capnocytophagia sepsis; response to fresh frozen plasma. 1997. Nephrology Dialysis Transplantation.
• Graham,K.A., Reaich,D., Channon,S.M., Downie,S., Goodship,T.H.J. Correction of acidosis in hemodialysis decreases whole-body protein degradation. Journal of the American Society of Nephrology 1997, 8, 632-637.
• Graham,K.A., Hoenich,N.A., Tarbit,M., Ward,M.K., Goodship,T.H.J. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. Journal of the American Society of Nephrology 1997, 8, 627-631.
• Graham,K.A., Goodship,T.H.J. The impact of maintenance hemodialysis on protein and energy requirements. Seminars in Dialysis 1997, 10, 82-86.
• Warwicker,P., Goodship,T.H.J., Goodship,J.A. Three new polymorphisms in the human complement factor H gene and promoter region. Immunogenetics 1997, 46, 437-438.
• Graham,K.A., Reaich,D., Channon,S.M., Downie,S., Gilmour,E., Passlick-Deetjen, J., Goodship,T.H.J. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney International 1996, 49, 1396-1400.
• Min,S.A.Y., Rutherford,P., Ward,M.K., Wheeler,J., Robertson,H., Goodship,T.H.J. Goodpasture's syndrome with normal renal function. Nephrology Dialysis Transplantation 1996, 11, 2302-2305.
• Roberts,R.G., Gilmour,E.R., Goodship,T.H.J. The correction of acidosis does not increase dietary protein intake in chronic renal failure patients. American Journal of Kidney Diseases 1996, 28, 350-353.
• Catalano,C., Goodship,T.H.J., Graham,K.A., Marino, C., Brown, A.L., Tapson, J.S., Ward,M.K., Wilkinson,R. Withdrawal of renal replacement therapy in Newcastle upon Tyne: 1964-1993. Nephrology Dialysis Transplantation 1996, 11, 133-139.
• Frith SE, Hoenich NA, Redfern CPF, Goodship THJ. Production of interleukin 1 receptor antagonist and interleukin 1 during haemodialysis with cellulose membranes. International Journal of Artificial Organs 1994, 17(9), 478-487.
• Haslam, P. J., Proctor, S. J., Goodship, T. H. J., Zouvani, J. Immune complex glomerulonephritis, myasthenia gravis and
  compensated hypothyroidism in a patient following allogeneic bone marrow transplantation. Nephrology Dialysis Transplantation 1993, 8(12), 1390-1392.